Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs MEDVidi

Two GLP-1 desks, one scoreboard. We put HealthRX and MEDVidi head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 446 · Grade C

MEDVidi

Visit MEDVidi Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 51 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make MEDVidi a bad call — it's best for people who want a licensed provider to prescribe brand glp-1 they fill with insurance. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
40
Supply Reliability
85
69
Transparency
83
27
Access Breadth
91
36
Clinical Oversight
89
77
Track Record
81
68
HealthRXBrief Score 86 · 51MEDVidi

Price, coverage & the tracker

HealthRXMEDVidi
Brief Score86/100 (B)51/100 (C)
Semaglutide$189/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageNot publicly listedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

MEDVidi: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.